By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Soligenix 

29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


SEARCH JOBS








Company News
Soligenix (SNGX) Release: Dusquetide Technology Platform To Be Presented At The 2017 Drug Discovery And Therapy World Congress 7/6/2017 7:32:07 AM
Soligenix (SNGX) Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 6/21/2017 8:30:40 AM
Soligenix (SNGX) Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference 6/19/2017 6:14:50 AM
Soligenix (SNGX) Announces Publication Of Its Phase II Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 5/18/2017 6:41:46 AM
Soligenix (SNGX) Announces Recent Accomplishments And First Quarter 2017 Financial Results 5/11/2017 9:15:33 AM
Soligenix (SNGX) Receives Japanese Patent For ThermoVax Vaccine Heat Stabilization Platform Technology 5/9/2017 7:10:07 AM
Soligenix (SNGX) Receives FDA Protocol Clearance Of Pivotal Phase III Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 5/3/2017 6:48:29 AM
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2016 Financial Results 3/27/2017 9:32:42 AM
Soligenix (SNGX) Receives European Patent For Formulation Of Synthetic Hypericin To Treat Psoriasis 2/22/2017 7:02:12 AM
Soligenix (SNGX) Announces SGX301 Receives Promising Innovative Medicine Designation From The UK Medicines And Healthcare Products Regulatory Agency 2/2/2017 8:14:18 AM
12345678910...
//-->